Elisabeth H. Thijssen

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration.

An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration.

Journal: Nature medicine

Published: November 18, 2025

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment.

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment.

Journal: Alzheimer's research & therapy

Published: April 06, 2023

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.

Journal: JAMA neurology

Published: April 03, 2023

Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia.

Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: September 28, 2021

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.

Journal: The Lancet. Neurology

Published: April 25, 2021

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.

Journal: The Lancet. Neurology

Published: December 09, 2020

Plasma p-tau217: from 'new kid' to most promising candidate for Alzheimer's disease blood test.

Plasma p-tau217: from 'new kid' to most promising candidate for Alzheimer's disease blood test.

Journal: Brain : a journal of neurology

Published: December 05, 2020

Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease.

Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease.

Journal: JAMA neurology

Published: November 09, 2020

Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease.

Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease.

Journal: Scientific reports

Published: November 04, 2020

Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis.

Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis.

Journal: Alzheimer's research & therapy

Published: September 10, 2020

Correction to: Relevance of biomarkers across different neurodegenerative diseases.

Correction to: Relevance of biomarkers across different neurodegenerative diseases.

Journal: Alzheimer's research & therapy

Published: June 11, 2020

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology.

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology.

Journal: Alzheimer's research & therapy

Published: June 08, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026